Biel is dependent on its Spanish subsidiary to grow. Spanish subsidiary of Portuguese medicine has invested 1.5 million euros in research and development (R&D) projects dedicated to advancing therapies against Parkinson’sAs Ana Alvarez, general director of the Biel business in Spain, told Plantados.
investment in progress Different Public-Private Hospitals in Spain, The collaboration seeks to implement and refine the introduction of the Ongentis drug developed by Biel in Parkinson’s patients in the country as well as introduce a sublingual film of apomorphine that dissolves under the tongue for acute and intermittent treatment . episode. Close In patients with this pathology.
The Portuguese group’s subsidiary in Spain has achieved revenues of 80 million euros this year and already represents 32% of the company’s total revenue. The company aims to increase sales to reach a turnover of 100 million euros in 2033.Although “it depends on the commercialization of the products we have planned,” admits Alvarez.
Biel generates 32% of its global turnover in Spain
In addition to investing in Parkinson’s and neurosciences, the company is also investing in respiratory research projectsWith products against obstructive pulmonary diseases that are already under study in Spain.
Biel’s subsidiary in Spain was born in 1998, when the group’s family parent bought Ifidesa Aristegui, a Basque company dedicated to immunotherapy and drug development, which at the time had a turnover of ten million euros. The company grew through different means partnerships with local companies.
With 135 people on staff and headquarters in Madrid, the group’s main lines of business are treatments against maladies such as epilepsy, Parkinson’s disease, asthma, COPD (chronic obstructive pulmonary disease), iron deficiency anemia or hypertension.
The Portuguese company has subsidiaries in Spain, Germany, the United Kingdom and Italy.
In addition to the Parkinson’s drug, the company’s other self-research product was commercially an anti-epileptic called Zebinix, which was launched on the market in 2011 and marketed throughout Europe, as the drug Ongentis.
The company, which was born in Portugal in 1924, has subsidiaries in Spain, Germany, the United Kingdom and Italy. Besides, It has a research center in Cambridge (Massachusetts) in the United States, which aims to study Parkinson’s.,
Parkinson’s disease in Spain, Biel’s main market, is a chronic and progressive neurodegenerative disorder characterized by a strong reduction in the neurotransmitter dopamine due to degeneration of certain neurons in the brain, affecting approximately ten million people in the world. . After Alzheimer’s, it is the second most common neurodegenerative disease.